Literature DB >> 21536000

A national epidemic of unintentional prescription opioid overdose deaths: how physicians can help control it.

Leonard J Paulozzi1, Richard H Weisler, Ashwin A Patkar.   

Abstract

Both the usage of prescription drugs such as opioid analgesics and benzodiazepines and overdoses involving them have increased dramatically in the United States since the 1990s. Patients using these drugs often have a combination of painful conditions, substance abuse, and other forms of mental illness. Psychiatrists and many primary care physicians might not be familiar with existing evidence-based guidelines for opioid prescribing or with programs designed to reduce the abuse of prescription drugs such as state prescription drug monitoring programs. Psychiatrists need to be informed regarding this problem to partner effectively with both pain specialists and primary care providers in their community. © Copyright 2011 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21536000     DOI: 10.4088/JCP.10com06560

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  39 in total

1.  Improving treatment for opioid dependence: a perspective from the Ohio Valley node of the NIDA Clinical Trials Network.

Authors:  Erin L Winstanley; Greg S Brigham; Dean Babcock; Theresa Winhusen
Journal:  Prog Community Health Partnersh       Date:  2014

2.  Policies and events affecting prescription opioid use for non-cancer pain among an insured patient population.

Authors:  Brian K Ahmedani; Edward L Peterson; Karen E Wells; David E Lanfear; L Keoki Williams
Journal:  Pain Physician       Date:  2014 May-Jun       Impact factor: 4.965

Review 3.  WHY NOT POT?: A Review of the Brain-based Risks of Cannabis.

Authors:  Kai MacDonald; Katherine Pappas
Journal:  Innov Clin Neurosci       Date:  2016-04-01

Review 4.  Harm reduction for young people who use prescription opioids extra-medically: Obstacles and opportunities.

Authors:  Brandon D L Marshall; Traci C Green; Jesse L Yedinak; Scott E Hadland
Journal:  Int J Drug Policy       Date:  2016-02-04

5.  Effect of Preoperative Opioid Exposure on Healthcare Utilization and Expenditures Following Elective Abdominal Surgery.

Authors:  Jennifer F Waljee; David C Cron; Rena M Steiger; Lin Zhong; Michael J Englesbe; Chad M Brummett
Journal:  Ann Surg       Date:  2017-04       Impact factor: 12.969

6.  Analgesic-Related Medication Errors Reported to US Poison Control Centers.

Authors:  Madhulika Eluri; Henry A Spiller; Marcel J Casavant; Thitphalak Chounthirath; Kristen A Conner; Gary A Smith
Journal:  Pain Med       Date:  2018-12-01       Impact factor: 3.750

7.  Incidence and predictors of new persistent opioid use following inflammatory bowel disease flares treated with oral corticosteroids.

Authors:  Mohamed Noureldin; Peter D R Higgins; Shail M Govani; Shirley Cohen-Mekelburg; Brooke C Kenney; Ryan W Stidham; Jennifer F Waljee; Akbar K Waljee
Journal:  Aliment Pharmacol Ther       Date:  2018-11-14       Impact factor: 8.171

8.  Prescription drug monitoring program inquiry in psychiatric assessment: detection of high rates of opioid prescribing to a dual diagnosis population.

Authors:  Daniel T Hackman; Marion S Greene; Taya J Fernandes; Ashley M Brown; Eric R Wright; R Andrew Chambers
Journal:  J Clin Psychiatry       Date:  2014-07       Impact factor: 4.384

9.  Mortality Rates Among Substance Use Disorder Participants in Clinical Trials: Pooled Analysis of Twenty-Two Clinical Trials Within the National Drug Abuse Treatment Clinical Trials Network.

Authors:  Robert Lindblad; Lian Hu; Neal Oden; Paul Wakim; Carmen Rosa; Paul VanVeldhuisen
Journal:  J Subst Abuse Treat       Date:  2016-08-15

10.  Do patient-perceived pros and cons of opioids predict sustained higher-dose use?

Authors:  Stephen M Thielke; Judith A Turner; Susan M Shortreed; Kathleen Saunders; Linda Leresche; Cynthia I Campbell; Constance C Weisner; Michael V Korff
Journal:  Clin J Pain       Date:  2014-02       Impact factor: 3.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.